Search research articles
Contact Us
Filters
Showing results (141-150 of 157) with videos related to
Page
of 16
Sort By:
European Heart Journal
|
May 1, 2014
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
Jean-Claude Tardif, Christie M Ballantyne, Philip Barter, et al.
European Journal of Preventive Cardiology
|
October 15, 2025
Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib
Jean-Claude Tardif, Marc A Pfeffer, Simon Kouz, et al.
The New England Journal of Medicine
|
November 7, 2007
Effects of torcetrapib in patients at high risk for coronary events
Philip J Barter, Mark Caulfield, Mats Eriksson, et al.
European Heart Journal
|
July 20, 2022
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
Jean Claude Tardif, Marc A Pfeffer, Simon Kouz, et al.
JAMA
|
June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis
David Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
Diabetes Care
|
January 5, 2024
Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
François Roubille, Nadia Bouabdallaoui, Simon Kouz, et al.
Circulation
|
February 19, 2004
Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: executive summary
Noel Bairey Merz, Robert O Bonow, George Sopko, et al.
European Heart Journal
|
August 30, 2020
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
Nadia Bouabdallaoui, Jean-Claude Tardif, David D Waters, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
May 15, 2020
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
Michelle Samuel, Jean-Claude Tardif, Paul Khairy, et al.
Journal of the American College of Cardiology
|
August 2, 2014
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials
S Matthijs Boekholdt, G Kees Hovingh, Samia Mora, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 157) with videos related to
Sort By:
Page
of 16
European Heart Journal
|
May 1, 2014
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
Jean-Claude Tardif, Christie M Ballantyne, Philip Barter, et al.
European Journal of Preventive Cardiology
|
October 15, 2025
Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib
Jean-Claude Tardif, Marc A Pfeffer, Simon Kouz, et al.
The New England Journal of Medicine
|
November 7, 2007
Effects of torcetrapib in patients at high risk for coronary events
Philip J Barter, Mark Caulfield, Mats Eriksson, et al.
European Heart Journal
|
July 20, 2022
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
Jean Claude Tardif, Marc A Pfeffer, Simon Kouz, et al.
JAMA
|
June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis
David Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
Diabetes Care
|
January 5, 2024
Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
François Roubille, Nadia Bouabdallaoui, Simon Kouz, et al.
Circulation
|
February 19, 2004
Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: executive summary
Noel Bairey Merz, Robert O Bonow, George Sopko, et al.
European Heart Journal
|
August 30, 2020
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
Nadia Bouabdallaoui, Jean-Claude Tardif, David D Waters, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
May 15, 2020
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
Michelle Samuel, Jean-Claude Tardif, Paul Khairy, et al.
Journal of the American College of Cardiology
|
August 2, 2014
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials
S Matthijs Boekholdt, G Kees Hovingh, Samia Mora, et al.
Page
of 16